Cargando…
Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
INTRODUCTION: Serum phosphorus management is important for patients with chronic kidney disease on dialysis to reduce the risk of hyperparathyroidism and ectopic vascular calcification. Phosphate binders (PBs) control serum phosphorus levels; however, some patients do not achieve adequate control wi...
Autores principales: | Nitta, Kosaku, Itoyama, Saki, Ikejiri, Kazuaki, Kinoshita, Jun, Nakanishi, Kaoru, Fukagawa, Masafumi, Akizawa, Tadao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658421/ https://www.ncbi.nlm.nih.gov/pubmed/38025211 http://dx.doi.org/10.1016/j.ekir.2023.08.003 |
Ejemplares similares
-
Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021) -
Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021) -
In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022) -
Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023) -
Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?
por: Wish, Jay B.
Publicado: (2023)